Submit Manuscript  

Article Details


New Human Monoamine Oxidase A Inhibitors with Potential Anti- Depressant Activity: Design, Synthesis, Biological Screening and Evaluation of Pharmacological Activity

[ Vol. 20 , Issue. 6 ]

Author(s):

Begum Evranos-Aksoz , Gulberk Ucar, Sadik Taskin Tas, Erkan Aksoz, Kemal Yelekci, Acelya Erikci, Yildirim Sara and Alper Bektas Iskit   Pages 461 - 473 ( 13 )

Abstract:


Aim and Objective: Depression is a momentous disease that can greatly reduce the quality of life and cause death. In depression, neurotransmitter levels such as serotonine, dopamine and noradrenaline are impaired. Monoamine oxidases (MAO) are responsible for oxidative catalysis of these monoamine neurotransmitters. Because of this relation, MAO-A inhibitors show antidepressant activity by regulating neurotransmitter levels. This study was carried out to investigate the design, synthesis and activity of new antidepressant compounds in pyrazoline and hydrazone structure.

Material and Method: Chalcones and hydrazides were heated under reflux to give new pyrazoline and hydrazone derivatives. Docking simulations were performed using AutoDock4.2. hMAO activities were determined by a fluorimetric method. To determine cell viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used. Behavioral activities of the three compounds were determined by using Forced Swim Test, Step-Through Passive Avoidance Test, Elevated Plus Maze and Open Field Arena Tests.

Results: According to in vitro tests, all of the synthesized compounds were found more potent than moclobemide and six of the synthesized compounds were found more selective than moclobemide. Three of the synthesized compounds were investigated for their behavioral activities comparing with moclobemide after 7 days of i.p. treatment at 30 mg/kg. One of the three compounds elicited significant antidepressant properties.

Conclusion: All of the synthesized compounds were found potent hMAO-A inhibitors in in vitro screening tests. Only one of the in vivo tested three compounds, (3-(2-hydroxy-5-methylphenyl)-5- p-tolyl-4,5-dihydropyrazol-1-yl)(pyridin-4-yl) methanone indicated significant antidepressant activity. This article opens a window for further development of new pyrazoline and hydrazone derivatives as antidepressant agents.

Keywords:

MAO-A inhibitors, antidepressant activity, molecular docking, 2-pyrazoline, hydrazone.

Affiliation:

Medicines and Medical Devices Agency, Analyses and Control Laboratories, Sıhhiye 06100, Ankara, Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Sıhhıye 06100, Ankara, Department of Medical Pharmacology, Faculty of Medicine, Hacettepe University, Altindag, Ankara 06100, Medicines and Medical Devices Agency, Analyses and Control Laboratories, Sıhhıye 06100, Ankara, Faculty of Engineering and Natural Sciences, Department of Bioinformatics and Genetics (Head) Cibali Campus, Kadir Has University, Fatih 34083, Istanbul, Department of Biochemistry, Faculty of Pharmacy, Hacettepe University, Sıhhıye 06100, Ankara, Department of Medical Pharmacology, Faculty of Medicine, Hacettepe University, Altindag, Ankara 06100, Department of Medical Pharmacology, Faculty of Medicine, Hacettepe University, Altindag, Ankara 06100



Read Full-Text article